This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Sumitomo Dainippon Pharma & Exscientia – New Drug Candidate Created Using AI begins Clinical Trial

Sumitomo Dainippon Pharma & Exscientia – New Drug Candidate Created Using AI begins Clinical Trial

30 Jan 2020

January 30, 2020 Sumitomo Dainippon Pharma Co., Ltd. Exscientia Ltd Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Trial Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan, Representative Director, President and CEO: Hiroshi Nomura) and Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) announce that a phase I clinical study of... Read more

The Oxford Science Park sponsors the OXBA Innovation Award for the fifth year

The Oxford Science Park sponsors the OXBA Innovation Award for the fifth year

13 Jan 2020

The Oxford Science Park sponsors the OXBA Innovation Award for the fifth year Apply now to join previous winners such as 2019’s Oxford Biomedica Oxford, UK, 13 January 2020 – Oxfordshire companies which are progressing valuable innovations can apply now for The Oxford Science Park Innovation Award, one of 2020’s Oxfordshire Business Awards (OXBA). The Oxford Science Park, one of the UK’s leading parks for science and technology companies, is... Read more

Bayer & Exscientia collaborate to leverage potential of AI in cardiovascular & oncology drug discovery

Bayer & Exscientia collaborate to leverage potential of AI in cardiovascular & oncology drug discovery

09 Jan 2020

Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered a collaboration with Bayer AG that aims to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology. Under terms of the agreement, Exscientia will initially work on three projects with targets agreed between both parties. Exscientia may be eligible to receive up to €240 Million, including... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More